Viewing Study NCT00789256

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:37 PM
Ignite Modification Date: 2025-12-25 @ 9:27 PM
Study NCT ID: NCT00789256
Status: COMPLETED
Last Update Posted: 2018-10-24
First Post: 2008-10-06
Is NOT Gene Therapy: False
Has Adverse Events: True
Brief Title: Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
Sponsor: Dartmouth-Hitchcock Medical Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myelogenous Leukemia View
None Myelodysplastic Syndromes View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Acute Myelogenous Leukemia View
None AML View
None Myelodysplastic Syndromes View
None MDS View
None Melphalan View
None Bortezomib View
None Velcade View